Risk factors
Mereo BioPharma Group (MREO) risk factors
Item 1A of every Mereo BioPharma Group plc 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors80 risks6 new3 dropped20 reworded
Drug-pricing pressure is newly tied to the May 2025 U.S. most-favored-nation executive order and potential international measures.
Filed Mar 19, 2026 - FY2024 10-K risk factors77 risks
Clinical-stage biopharmaceutical company with cumulative losses and no product revenue, developing setrusumab, alvelestat, etigilimab, acumapimod, and leflutrozole.
Filed Mar 26, 2025